



**Patient Cases - Plasma Cell Dyscrasia (PCD) - 6/26/2025  
6/26/2025 12:00:00 PM - 6/26/2025 1:30:00 PM**

By texting in your attendance, you will be awarded the maximum number of CE credits. If you wish to claim less than the maximum CE credits, please contact [MDAnderson-CPE@mdanderson.org](mailto:MDAnderson-CPE@mdanderson.org)

**Target Audience:**

Professions: Physician (MD or DO), Nurse - RN, Nurse - APRN

**Learning Objectives:**

- 1 Incorporate awareness among healthcare providers and implementing standardized screening protocols to identify cases.
- 2 Promote the use of advanced diagnostic techniques to improve accuracy and early detection of Plasma Cell Dyscrasia (PCD).

**Accreditation:**



In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Credit Designation:**

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity will award 1.50 Nursing Contact Hour(s)

**Commercial Support:**

No commercial support has been received for this activity.

**Disclosure of Financial Relationships:**

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Behrang Amini, MD	Other Planning Committee Member	Independent Contractor (included contracted research)- ImpactBio   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Deciphera - 09/26/2024
Robert Z. Orlowski, MD	Other Planning Committee Member	Grant or research support-Bristol-Myers Squibb Company   Advisor-CellCentric   Grant or research support-CARSgen Therapeutics   Grant or research support-Exelixis (Relationship has ended)   Grant or research support-Heidelberg Pharma   Grant or research support-Janssen Biotech, Inc.   Grant or research support-Sanofi Genzyme   Grant or research support-Millennium Pharmaceuticals, Inc., The Takeda Oncology Company   Grant or research support-Asyria Therapeutics (Relationship has ended)   Advisor-AbbVie Inc. (Relationship has ended)   Advisor-Adaptive Biotech (Relationship has ended)   Advisor-Karyopharm Therapeutics (Relationship has ended)   Advisor-Meridian Therapeutics   Advisor-Monte Rosa Therapeutics (Relationship has ended)   Advisor-Nanjing IASO Biotherapeutics   Advisor-Neoleukin Corporation (Relationship has ended)   Advisor-Oncopeptides AB   Advisor-Regeneron Pharmaceuticals, Inc.   Advisor-Millennium Pharmaceuticals, Inc., The Takeda Oncology Company   Advisor-Asyria Therapeutics, Inc. (Relationship has ended)   Advisor-BioTheryX (Relationship has ended)   Advisor-Bristol-Myers Squibb Company   Advisor-Pfizer Inc.   Advisor-Lytica Therapeutics - 05/05/2025
Andres E Quesada, MD	Activity Co-Director, Faculty	Nothing to disclose - 11/20/2024
Tiffany Richards, PhD, AN-BC, AOCNP	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc.   Membership on Advisory Committees or Review Panels,

		Board Membership, etc.- GlaxoSmithKline   Consulting Fee- Regeneron Pharmaceuticals, Inc. - 03/03/2025
Jing Christine Ye, MD	Activity Director	Advisor-Janssen Biotech, Inc.   Consulting Fee-Pfizer Inc.   Honoraria-Sanofi US (Relationship has ended) - 01/20/2025